Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Capitol Hill Briefs: Device Tax Repeal; Clinical Trials; DME Bidding

This article was originally published in The Gray Sheet

Executive Summary

Legislation introduced in the new Republican-controlled Senate include device tax repeal, a measure that would allow Medicaid recipients to enroll in clinical trials and a bill, introduced in parallel in the House, aimed at stopping non-binding bids for supplying durable medical equipment, prosthetics, orthotics and supplies.

You may also be interested in...



Industry Looking To New GOP Congress To Repeal Device Tax

AdvaMed says a new Congressional Research Service report underestimates the number of people likely to lose their jobs because of the tax and is looking forward to a new Republican Congress focused on repealing it.

News Briefs: Panel OKs Sleep Apnea Stimulator; Two Stryker Buys; TAVR Updates

FDA panel unanimously endorses Inspire upper airway stimulator. Stryker buys Berchtold and Pivot. First randomized U.S. study of embolic protection during transcatheter aortic valve replacement approved. More news.

Veru Hopes To Position Enobosarm As Muscle-Protective In Weight-Loss Therapy

A selective androgen receptor modulator also being studied in metastatic breast cancer, enobosarm might offer potential as add-on therapy to GLP-1 agonists prescribed for weight loss, the Miami biotech asserts.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034060

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel